GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alector Inc (NAS:ALEC) » Definitions » Profitability Rank

Alector (Alector) Profitability Rank : 3 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Alector Profitability Rank?

Alector has the Profitability Rank of 3. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Alector's Operating Margin % for the quarter that ended in Dec. 2023 was -312.40%. As of today, Alector's Piotroski F-Score is 0.


Competitive Comparison of Alector's Profitability Rank

For the Biotechnology subindustry, Alector's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alector's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alector's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Alector's Profitability Rank falls into.



Alector Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Alector has the Profitability Rank of 3. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Alector's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-47.453 / 15.19
=-312.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 0 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Alector has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Good Sign:

Alector Inc operating margin is expanding. Margin expansion is usually a good sign.

4. Consistency of the profitability

5. Predictability Rank


Alector Profitability Rank Related Terms

Thank you for viewing the detailed overview of Alector's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Alector (Alector) Business Description

Traded in Other Exchanges
Address
131 Oyster Point Boulevard, Suite 600, South San Francisco, CA, USA, 94080
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Executives
Sara Kenkare-mitra officer: President and Head of R&D C/O ALECTOR, INC, 131 OYSTER POINT BLVD, SUITE 600, SOUTH SAN FRANCISCO CA 94080
Gary Romano officer: Chief Medical Officer TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Arnon Rosenthal director, officer: Chief Executive Officer C/O ALECTOR, INC., 151 OYSTER POINT BLVD., #300, SOUTH SAN FRANCISCO CA 94080
Marc Grasso officer: Chief Financial Officer C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO CA 92121
Terrance Mcguire director, 10 percent owner C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
Polaris Venture Management Co. Vi, L.l.c. 10 percent owner ONE MARINA PARK DRIVE, 8TH FLOOR, BOSTON MA 02210
Richard H Scheller director C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Paula Hammond director C/O ALECTOR, INC., 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA 94080
Kristine Yaffe director C/O ALECTOR, INC., 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO CA 94080
Tillman U. Gerngross director C/O ARSANIS, INC., 890 WINTER STREET, SUITE 230, WALTHAM MA 02451
Lavigne Louis J Jr director C/O ALLERGAN, INC., 2525 DUPONT DRIVE, IRVINE CA 92612
Elizabeth A. Garofalo director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
David M. Wehner director C/O FACEBOOK, INC., 1601 WILLOW ROAD, MENLO PARK CA 94025
Robert King officer: Chief Development Officer 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Shehnaaz Suliman officer: President and COO 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080